Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for treatment of diabetes

A composition and technology for diabetes, applied in the directions of drug combination, pharmaceutical formula, metabolic diseases, etc., can solve the problem of undocumented administration methods, and achieve the effects of effective treatment, reduced side effects, and high therapeutic effect.

Inactive Publication Date: 2008-02-06
DAIICHI SANKYO CO LTD
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the specific administration method of the present invention has not yet been documented

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treatment of diabetes
  • Pharmaceutical composition for treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] 2-Amino-5-isobutyl-4-{2-[5-(N,N'-bis((S)-1-ethoxycarbonyl)ethyl)phosphonamido]furan administered at specific times Effect of base} thiazole (compound A) and metformin on improving diabetes

[0061] The 11-week-old Zucker diabetic fat (ZDF) rats with diabetes onset were divided into three groups (7 / group), and the feeding time was limited from 17:00 to 9:00. Compound A and metformin (purchased from Sigma Chemical (strain)) repeated administration for 6 weeks. The doses of compound A and metformin are both 100-150 mg / kg each time per day, administered at 9:00 am (9:00) or 4:00 pm (16:00) in the afternoon. The group given Compound A at 9 am was given metformin at 4 pm (am-compound A / pm-metformin administered group; group A), and the group given metformin at 9 am was given compound A at 4 pm (am-metformin / Afternoon-compound A administration group; B group), the daily doses of the compound were equalized for both groups, and only the vehicle was administered twice a day ...

Embodiment 2

[0073] Dietary Response to 2-Amino-5-isobutyl-4-{2-[5-(N,N'-bis((S)-1-ethoxycarbonyl)ethyl)phosphonamido]furyl}thiazole (compound A) the effect of improving the effect of diabetes

[0074] Diabetic 36-week-old male Goto-Kakizaki (GK) rats (marketed by Charles River, Japan) were divided into a non-fasting control group, a non-fasting Compound A administration group, a fasting control group, and a fasting Compound A administration group. Group (6 / group).

[0075] Compound A (30 mg / kg) was orally administered to the compound A-administered group, and only the administration vehicle was orally administered to the control two groups. The fasting group started the day before the oral administration of compound A, and the non-fasting group started the fasting immediately after the oral administration of compound A (free intake of solid feed (FR2, manufactured by Funabashi Farm) before the start of fasting) ). Immediately before orally administering Compound A and 4 hours after the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

It is intended to provide a method of treating diabetes which exhibits an excellent effect, enables the regulation of side effects and has a high safety. To use a drug containing an FBPase inhibitor at a definite dosing point.

Description

technical field [0001] The present invention relates to a therapeutic drug containing an FBPase inhibitor as an active ingredient, which has a high therapeutic effect on diabetes, hyperglycemia, impaired glucose tolerance, obesity, diabetic complications (preferably diabetes), and can reduce side effects, and administration of the therapeutic drug method. [0002] The present invention also relates to a therapeutic drug containing an FBPase inhibitor and other therapeutic drugs for diabetes, which has a high therapeutic effect on diabetes, hyperglycemia, impaired glucose tolerance, obesity, diabetic complications (preferably diabetes), and can reduce side effects, and The method of administration of the therapeutic drug. Background technique [0003] FBPase inhibitors are known to exert the effect of lowering blood sugar by inhibiting gluconeogenesis in the liver, and are considered to be effective in diabetes mellitus, hyperglycemia, impaired glucose tolerance, obesity, di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/155A61K31/427A61P3/10
CPCA61K31/427A61K31/155A61P3/10A61K45/00
Inventor 吉田大志奥野晃
Owner DAIICHI SANKYO CO LTD